Skip to content

Study · Not a test of the peptide alone · 2026

3 results

Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.

Chawathe A, Sharma N

Journal of pharmaceutical and biomedical analysis14 Jan 2026

PMID41547183 (opens in a new tab)DOI10.1016/j.jpba.2026.117362 (opens in a new tab)PepBankPUB-41547183
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cell-free)Other

    In forced degradation tests, afamelanotide degraded under all applied stress conditions, producing fourteen degradation products.

    In plain wordsIn lab tests, afamelanotide broke down under every stress condition tested and formed fourteen degradation products.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableDegradation under stress conditions
    Study

    n: not reported in source

    Forced degradation under stress conditions
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    afamelanotide undergoes degradation under all applied stress conditions with the generation of fourteen different degradation products (DPs)
    1 context sentence
    Summary · context
    The current work endeavours to explore afamelanotide's degradation pathways under various chemical and physical stress conditions: acidic, basic, neutral, and oxidative stress, UV light exposure, and increased temperature at 60⁰C.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cell-free)Other

    In forced degradation tests, afamelanotide degraded by truncation, methylation, deacetylation and oxidation.

    In plain wordsIn lab tests, afamelanotide broke down by truncation, methylation, deacetylation and oxidation.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableDegradation pathways
    Study

    n: not reported in source

    Forced degradation under stress conditions
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    this work has identified several degradation pathways such as truncation, methylation, deacetylation, and oxidation
    1 context sentence
    Summary · context
    The current work endeavours to explore afamelanotide's degradation pathways under various chemical and physical stress conditions: acidic, basic, neutral, and oxidative stress, UV light exposure, and increased temperature at 60⁰C.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cell-free)Other

    A gradient reversed-phase HPLC method separated the afamelanotide degradation products and was validated according to the ICH Q2(R1) guideline.

    In plain wordsIn lab tests, an HPLC method separated afamelanotide and its breakdown products and met the ICH Q2(R1) validation guideline.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableHPLC method validation
    Study

    n: not reported in source

    Forced degradation under stress conditions
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    which were separated by gradient reversed-phase HPLC on a Zorbax SB C18 column (300 Å, 4.6*150 mm, 3.5 µm) and the method was validated according to the ICH Q2(R1) guideline
    1 context sentence
    Summary · context
    The current work endeavours to explore afamelanotide's degradation pathways under various chemical and physical stress conditions: acidic, basic, neutral, and oxidative stress, UV light exposure, and increased temperature at 60⁰C.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.